Greg Harrison
Stock Analyst at Scotiabank
(4.53)
# 270
Out of 5,147 analysts
103
Total ratings
59.49%
Success rate
20.93%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $495 → $558 | $496.83 | +12.31% | 8 | Feb 13, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $34 | $30.23 | +12.47% | 9 | Dec 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $13.78 | +117.71% | 3 | Oct 27, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $503.90 | -8.12% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $29.26 | +46.96% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $29.79 | +4.06% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $8.94 | +123.71% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $66.48 | -14.26% | 7 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $332.92 | +35.17% | 6 | Aug 1, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $0.42 | +2,488.84% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $8.23 | +325.27% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $40.79 | +34.84% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $19 | $5.01 | +279.24% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $31.02 | +19.28% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $14.19 | +83.23% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $20.96 | -4.58% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.68 | -10.71% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $28.46 | +40.55% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $66.62 | +12.58% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $17.56 | +2.51% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $36.41 | -67.04% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.43 | +246.98% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.20 | +581.82% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $12.05 | -75.10% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.94 | +7,316.04% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $13.12 | +311.59% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $68.98 | +30.47% | 5 | Mar 14, 2022 |
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Sector Perform
Price Target: $495 → $558
Current: $496.83
Upside: +12.31%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $34
Current: $30.23
Upside: +12.47%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $13.78
Upside: +117.71%
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $503.90
Upside: -8.12%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $29.26
Upside: +46.96%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $29.79
Upside: +4.06%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $8.94
Upside: +123.71%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $66.48
Upside: -14.26%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $332.92
Upside: +35.17%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $0.42
Upside: +2,488.84%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $8.23
Upside: +325.27%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $40.79
Upside: +34.84%
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $5.01
Upside: +279.24%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $31.02
Upside: +19.28%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $14.19
Upside: +83.23%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $20.96
Upside: -4.58%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.68
Upside: -10.71%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $28.46
Upside: +40.55%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $66.62
Upside: +12.58%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $17.56
Upside: +2.51%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $36.41
Upside: -67.04%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.43
Upside: +246.98%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.20
Upside: +581.82%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $12.05
Upside: -75.10%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $0.94
Upside: +7,316.04%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $13.12
Upside: +311.59%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $68.98
Upside: +30.47%